Literature DB >> 33379235

Impact of Pneumococcal Vaccination in the Nasopharyngeal Carriage of Streptococcus pneumoniae in Healthy Children of the Murcia Region in Spain.

Santiago Alfayate Miguélez1, Genoveva Yague Guirao2, Ana I Menasalvas Ruíz1, Manuel Sanchez-Solís1, Mirian Domenech Lucas3, Fernando González Camacho3, M Mar Ortíz Romero4, Pilar Espejo García5, Carmen Guerrero Gómez6, Antonio Iofrío de Arce7, Laura Moreno Parrado8, Rosa M Sánchez Andrada9, Eva Cascales Alcolea10, Sebastián Lorente García11, Pedro Paredes Reyes2, Ángela Casquet Barceló12, M Luisa López Yepes13, Juan José Vigueras Abellán14, Gonzalo Sanz Mateo15.   

Abstract

BACKGROUND: An epidemiological study of Streptococcus pneumoniae nasopharyngeal carriage in healthy children was carried out five years after the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13).
OBJECTIVES: Study the impact of pediatric vaccination with PCV13, and other associated epidemiological factors on the status of nasopharyngeal carriage, the circulating pneumococcal serotypes, and the antibiotic susceptibility to more frequently used antibiotics.
METHODS: A multi-center study was carried out in Primary Health Care, which included 1821 healthy children aged 1 to 4 years old. All isolates were sent to the Spanish Pneumococcal Reference Laboratory for serotyping and antimicrobial susceptibility testing.
RESULTS: At least one dose of PCV13 had been received by 71.9% of children and carriage pneumococcal prevalence was 19.7%. The proportion of PCV13 serotypes was low (14.4%), with an observed predominance of non-vaccine serotypes, 23B, 11A, 10A, 35B/F, and 23A were the five most frequent. A high rate of resistance to penicillin, erythromycin, and trimethoprim sulfamethoxazole was found.
CONCLUSIONS: A low proportion of PCV13 serotypes were detected, confirming the impact of pediatric vaccination for reducing the serotypes vaccine carriage. High resistance rates to clinically important antibiotics were observed.

Entities:  

Keywords:  Streptococcus pneumoniae nasopharyngeal carriage; antimicrobial susceptibility; conjugate vaccines

Year:  2020        PMID: 33379235      PMCID: PMC7823743          DOI: 10.3390/vaccines9010014

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  40 in total

1.  [Nasopharyngeal carriage of pneumococcal serotypes in healthy pre-school aged children after 7-valent pneumococcal vaccine].

Authors:  César García-Vera; María Ángeles Ruiz Andrés; Teresa Arana Navarro; Isabel Moneo Hernández; José Antonio Castillo Laita; Rosa Macipe Costa; María José Revillo Pinilla
Journal:  Med Clin (Barc)       Date:  2011-04-22       Impact factor: 1.725

2.  Impact of 13-Valent Pneumococcal Conjugate Vaccination on Streptococcus pneumoniae Carriage in Young Children in Massachusetts.

Authors:  Grace M Lee; Ken Kleinman; Stephen I Pelton; William Hanage; Susan S Huang; Matthew Lakoma; Maya Dutta-Linn; Nicholas J Croucher; Abbie Stevenson; Jonathan A Finkelstein
Journal:  J Pediatric Infect Dis Soc       Date:  2013-10-03       Impact factor: 3.164

3.  Changing serotype distribution and resistance patterns among pediatric nasopharyngeal pneumococci collected in Moscow, 2010-2017.

Authors:  Nikolai Mayanskiy; Tatiana Kulichenko; Natalia Alyabieva; Ekaterina Brzhozovskaya; Olga Ponomarenko; Tatiana Savinova; Anna Lazareva
Journal:  Diagn Microbiol Infect Dis       Date:  2019-02-16       Impact factor: 2.803

4.  Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective surveillance study.

Authors:  Naïm Ouldali; Emmanuelle Varon; Corinne Levy; François Angoulvant; Scarlett Georges; Marie-Cécile Ploy; Marie Kempf; Julie Cremniter; Robert Cohen; Daniel Levy Bruhl; Kostas Danis
Journal:  Lancet Infect Dis       Date:  2020-07-20       Impact factor: 25.071

Review 5.  Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines.

Authors:  Joseph P Lynch; George G Zhanel
Journal:  Curr Opin Pulm Med       Date:  2010-05       Impact factor: 3.155

6.  Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study.

Authors:  Camelia Savulescu; Pavla Krizova; Agnes Lepoutre; Jolita Mereckiene; Didrik F Vestrheim; Pilar Ciruela; Maria Ordobas; Marcela Guevara; Eisin McDonald; Eva Morfeldt; Jana Kozakova; Emmanuelle Varon; Suzanne Cotter; Brita A Winje; Carmen Munoz-Almagro; Luis Garcia; Jesus Castilla; Andrew Smith; Birgitta Henriques-Normark; Lucia Pastore Celentano; Germaine Hanquet
Journal:  Lancet Respir Med       Date:  2017-03-27       Impact factor: 30.700

7.  Nationwide Trends of Invasive Pneumococcal Disease in Spain From 2009 Through 2019 in Children and Adults During the Pneumococcal Conjugate Vaccine Era.

Authors:  Sara de Miguel; Mirian Domenech; Fernando González-Camacho; Julio Sempere; Dolores Vicioso; Juan Carlos Sanz; Luis García Comas; Carmen Ardanuy; Asunción Fenoll; Jose Yuste
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

8.  Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study.

Authors:  Shamez N Ladhani; Sarah Collins; Abdelmajid Djennad; Carmen L Sheppard; Ray Borrow; Norman K Fry; Nicholas J Andrews; Elizabeth Miller; Mary E Ramsay
Journal:  Lancet Infect Dis       Date:  2018-01-26       Impact factor: 25.071

9.  Nasopharyngeal Pneumococcal Carriage among Healthy Children in Cyprus Post Widespread Simultaneous Implementation of PCV10 and PCV13 Vaccines.

Authors:  Adamos Hadjipanayis; Elisavet Efstathiou; Maria Alexandrou; Loukia Panayiotou; Chrystalla Zachariadou; Panayiotis Petrou; Vasiliki Papaevangelou
Journal:  PLoS One       Date:  2016-10-05       Impact factor: 3.240

10.  Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program.

Authors:  Lukas Richter; Daniela Schmid; Elisabeth Eva Kanitz; Ines Zwazl; Eva Pöllabauer; Joanna Jasinska; Heinz Burgmann; Michael Kundi; Ursula Wiedermann
Journal:  PLoS One       Date:  2019-01-10       Impact factor: 3.240

View more
  4 in total

1.  Impact of Pneumococcal Vaccination on Nasopharyngeal Carriage of Streptococcus pneumoniae and Microbiota Profiles in Preschool Children in South East Poland.

Authors:  Karolina Kielbik; Aleksandra Pietras; Joanna Jablonska; Adrian Bakiera; Anna Borek; Grazyna Niedzielska; Michal Grzegorczyk; Ewelina Grywalska; Izabela Korona-Glowniak
Journal:  Vaccines (Basel)       Date:  2022-05-17

2.  Increase of Macrolide-Resistance in Streptococcus pneumoniae Strains After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Lima, Peru.

Authors:  Brayan E Gonzales; Erik H Mercado; Maria Pinedo-Bardales; Noemi Hinostroza; Francisco Campos; Eduardo Chaparro; Olguita Del Águila; María E Castillo; Andrés Saenz; Isabel Reyes; Theresa J Ochoa
Journal:  Front Cell Infect Microbiol       Date:  2022-05-09       Impact factor: 6.073

3.  Structural, Genetic, and Serological Elucidation of Streptococcus pneumoniae Serogroup 24 Serotypes: Discovery of a New Serotype, 24C, with a Variable Capsule Structure.

Authors:  Feroze Ganaie; Karsten Maruhn; Chengxin Li; Richard J Porambo; Pernille L Elverdal; Chitrananda Abeygunwardana; Mark van der Linden; Jens Ø Duus; Carmen L Sheppard; Moon H Nahm
Journal:  J Clin Microbiol       Date:  2021-06-18       Impact factor: 5.948

4.  Induction of Susceptibility to Disseminated Infection with IgA1 Protease-Producing Encapsulated Pathogens Streptococcus pneumoniae, Haemophilus influenzae Type b, and Neisseria meningitidis.

Authors:  Mogens Kilian; Steffen Husby; Jesper Andersen; Zina Moldoveanu; Uffe B Skov Sørensen; Jesper Reinholdt; Hervé Tettelin
Journal:  mBio       Date:  2022-04-14       Impact factor: 7.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.